Pulmonary Emphysema — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for pulmonary emphysema. 238 active patents protecting 4 drugs from 4+ originators. First major cliff: 2027. Daily refresh.

4
Approved drugs
238
Active US patents
62/100
Avg vulnerability
$5.7B
Annual revenue covered

Originators in Pulmonary Emphysema

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Pfizer Inc. 70 patents Haleon Us Holdings 41 patents Boehringer Ingelheim 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating pulmonary emphysema. Each bar = one year. Y-axis scaled to peak year (53 patents).

7
26
14
27
10
28
12
29
21
30
35
31
8
34
22
35
10
36
6
37
4
38
53
39
28
40
7
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Epipen
epinephrine
 Pfizer Inc. 70 61 — 2026-12-12
Arnuity Ellipta
FLUTICASONE FUROATE
 Haleon Us Holdings 41 61 $3.1B 2027-06-14
Spiriva
TIOTROPIUM BROMIDE
 Boehringer Ingelheim 9 68 $2.5B 2026-07-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8511304 Arnuity Ellipta method of use 83 2027-06-14
11116721 Arnuity Ellipta method of use 83 2029-02-26
12083270 Cutivate method of use 81 2031-04-04
8022082 Spiriva other 80 2026-07-19
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
7396341 Spiriva other 80 2027-04-10
8511304 Arnuity Ellipta method of use 80 2027-06-14
8511304 Arnuity Ellipta method of use 75 2027-06-14
9027967 Spiriva other 75 2027-09-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06
10918816 Cutivate formulation 42 2035-12-14
10918816 Cutivate formulation 42 2035-12-14

Related